DCC5311 |
Ugm-in-1 |
Novel inhibitor of UGM, impeding C. glutamicum growth |
|
DCC5312 |
Ugm-in-2 |
Novel inhibitor of UGM, impeding C. glutamicum growth |
|
DCC5313 |
Uic-94003 |
Novel potent human immunodeficiency virus type 1 (HIV-1) protease inhibito |
|
DCC5314 |
Uk-447841 |
Selective NEP inhibitor for treatment of the symptoms of Female sexual arousal disorder (FSAD) |
|
DCC5315 |
Uk-505749 |
Selective NEP inhibitor for treatment of the symptoms of Female sexual arousal disorder (FSAD) |
|
DCC5316 |
Ukcp-110 |
Potent VMAT2 inhibitor |
|
DCC5317 |
Ul-766 |
Novel chemically stable fluorescent marker of the ureter |
|
DCC5318 |
Um1024 |
Novel Vaccine Adjuvant for Mycobacterium tuberculosis |
|
DCC5319 |
Umb103 |
Novel potent and selective dual PLK1 and BRD4 inhibitor, inducing apoptosis in pediatric tumor cell lines, leading to significant tumor regression |
|
DCC5320 |
Umb298 |
Novel, Potent, and Selective CBP/P300 Inhibitor |
|
DCC5321 |
Umc160 |
Novel Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitor |
|
DCC5322 |
Um-c162 |
Novel anti-virulence agent, rescuing nematodes from a Staphylococcus aureus infection and preventing the formation of biofilm in a dose-dependent manner without interfering with bacterial viability |
|
DCC5323 |
Unag Ligand |
Novel fluorescent UnaG ligand, binding UnaG with high affinity (Kd = 3 nM) to induce a 2.5-fold fluorescence intensity enhancement and a 10 nm red shift |
|
DCC5324 |
Unbs3157 |
Novel nonhematotoxic DNA intercalating agent with potent antitumor activity, inducing apoptosis via inhibition of key proteins in the PI3K/Akt/mTOR signaling pathway |
|
DCC5325 |
Unc0737
Featured
|
UNC0737 is a negative control of UNC0638 and the N-methyl analog of UNC0638. UNC0737 was designed to eliminate the hydrogen bond interaction seen in the G9a-UNC0224 cocrystal structure between Asp1083 of G9a and the secondary amino group at the 4-position of UNC0224's quinazoline ring3. UNC0737 was >300-fold less potent than UNC0638 in G9a and GLP biochemical assays. As expected, UNC0737 was a poor inhibitor of G9a (IC50 = 5,000 ± 200 nM (n = 2)) and GLP (IC50 > 10,000 nM (n = 2)) in the SAHH-coupled assays. |
|
DCC5326 |
Unc0965 |
Biotinylated UNC0638, enabling chemiprecipitation of G9a from whole cell lysates |
|
DCC5327 |
Unc10112731 |
Novel MYC protein stablizer, increasing the abundance of endogenous MYC proteintargeting the receptor tyrosine kinases KIT and platelet-derived growth factor receptor α (PDGFRα) |
|
DCC5328 |
Unc10112749a |
Novel inhibitor of ROP18, inhibiting ROP18 within cells, and abrogating its effects on the host IRG pathway |
|
DCC5329 |
Unc10245092 |
Novel Peptide Inhibitor for Calcium and Integrin Binding Protein 1 (CIB1) |
|
DCC5330 |
Unc1653 |
Negative control for UNC1666 which is a dual Mer and Flt-3 tyrosine kinase inhibitor |
|
DCC5331 |
Unc32a |
Orally Active Adenosine A 1 Receptor Agonist |
|
DCC5332 |
Unc4859 |
Novel Ligand of EEDm acting as an allosteric inhibitor of PRC2 |
|
DCC5333 |
Unc5114 |
Novel allosteric inhibitor of PRC2 catalytic activity |
|
DCC5334 |
Unc5115 |
Novel allosteric inhibitor of PRC2 catalytic activity |
|
DCC5335 |
Unc5635 |
Novel selective activator of PRC2-EED-I363M, showing minimal effects on the activity of PRC2-WT |
|
DCC5336 |
Unc5636 |
Novel selective activator of PRC2-EED-I363M, showing minimal effects on the activity of PRC2-WT |
|
DCC5337 |
Unc6212 |
Novel inhibitor for histone methyllysine reader proteins (KmeRP), targeting CBX5 chromodomain |
|
DCC5338 |
Unc6349 |
Novel inhibitor for histone methyllysine reader proteins (KmeRP), targeting CBX5 chromodomain |
|
DCC5339 |
Unc6641 |
Novel peptidomimetic antagonist of the PHF1 Tudor domain, binding both PHF1 Tudor domain and the related protein PHF19 |
|
DCC5340 |
Unc6864 |
Novel inhibitor for histone methyllysine reader proteins (KmeRP), targeting CBX5 chromodomain |
|